Arrowhead Pharmaceuticals (ARWR) vs Axsome Therapeutics (AXSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 64.4% versus a gain of 43.3%. Over five years, AXSM leads with a +324.1% price change compared with -8.2% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($8.86 billion vs $8.82 billion), about 1.0 times the size.
Arrowhead Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.2% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | AXSM |
|---|---|---|
| Share price | $62.75 | $168.35 |
| Market cap | $8.86B | $8.82B |
| 1-day change | +3.31% | -1.02% |
| YTD return | -8.51% | -6.88% |
| 1-year return | +64.43% | +43.27% |
| 5-year return | -8.19% | +324.14% |
| Forward P/E | — | 35.80 |
| EPS (TTM) | $-2.28 | $-3.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $638.50M |
| Revenue growth (YoY) | +23258.15% | +65.55% |
| Net income (latest FY) | $-1.63M | $-183.17M |
| Gross margin | — | 92.56% |
| Operating margin | 11.86% | -26.12% |
| Net margin | -0.20% | -28.69% |
| 52-week high | $95.49 | $260.19 |
| 52-week low | $34.61 | $119.20 |
| Distance from 52-week high | -34.29% | -35.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.88% | +69.07% |
| Average volume | 1.91M | 712.30K |
| Shares outstanding | 141.25M | 52.38M |
| Employees | 711 | 1,346 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed AXSM by 21.2 percentage points over the past year.
- Arrowhead Pharmaceuticals is more profitable, keeping -0.2 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +65.55%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
ARWR vs AXSM FAQ
Which is bigger, Arrowhead Pharmaceuticals or Axsome Therapeutics?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $8.86B compared with $8.82B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, ARWR or AXSM?
ARWR returned +64.43% over the past 12 months, compared with +43.27% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Axsome Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.